Medtronic Releases Positive Study Results on Pacemaker

美美敦力发布Micra经导管起搏系统改善心脏功能积极研究结果

2019-11-13 13:30:01 YAHOO!FINANCE

本文共1739个字,阅读需5分钟

Medtronic plc MDT recently announced favorable data from its study on MARVEL 2 . The study results demonstrate that an investigational set of algorithms in the Micra Transcatheter Pacing System significantly improves synchrony and cardiac function in patients with impaired electrical conduction between the chambers of the heart, called atrioventricular block.The company will present the results of MARVEL 2 on Nov 16 during a Featured Science session at American Heart Association 2019, the AHA Scientific Sessions.Based on the favorable outcomes, Medtronic submitted a new leadless pacemaker to the FDA for review, with an aim to expand the indicated population to AV block and normal sinus rhythm. With this, the company aims to strengthen foothold in the leadless pacemaker market on the back of the favorable outcome of the study. A Closer Look at the Micra PortfolioPer the company, the Micra TPS is the only leadless pacemaker approved for use by the FDA in the United States. The Micra TPS is much smaller in size compared to the traditional pacemakers, delivering the most advanced pacing technology to patients through a minimally invasive approach. The Micra is innovative as the TPS can be permanently switched off as per requirement.Why is the Study a Breakthrough?Per the company, the outcomes indicate that there will be an improvement in the coordination between the atrium and ventricle sections of the heart as a result of the upgraded to the Micra TPS. This improves outreach for patients, who are eligible to be treated with the leadless pacemaker.The MARVEL 2 study assessed 75 patients worldwide with a Micra TPS, out of which 40 patients had complete heart block and normal sinus rhythm and were eligible for inclusion in the primary efficacy analysis. There were no abnormal occurrences in meeting the safety objective of the study — its primary endpoint.Recent DevelopmentsOf late, Medtronic has been witnessing a slew of innovation related to its cardiac and vascular business.The company launched the Valiant Navion thoracic stent graft system in Japan for the minimally invasive repair of thoracic descending aortic aneurysms (TAA) and complicated type B aortic dissections (TBAD) in October. The Valiant Navion is an improvement to the already existing Valiant Captivia thoracic stent graft system. Again, in the same month, the company launched its advanced Patient Programmer technology for Deep Brain Stimulation (DBS) therapy, which allows patients to manage their therapy more simply and discreetly.Further, in October, the company also received the Breakthrough Device designation from the FDA for Fully Implantable Left Ventricular Assist Device (LVAD) and Valiant thoracoabdominal aortic aneurysm (TAAA) stent graft system. The Fully Implantable LVAD is currently in the development stage and intended for patients with advanced heart failure. The Valiant TAAA stent graft system is to be used for minimally invasive repair of TAAA.In September, Medtronic received FDA nod for Evolut PRO+ TAVR System, which is an innovative transcatheter aortic valve replacement (TAVR) system that builds off the proven self-expanding, supra-annular Evolut TAVR platform.Industry ProspectsPer a report by ResearchAndMarkets, the global leadless cardiac pacemakers market is anticipated to reach $269.8 million by 2026 from $47.1 million in 2017, expanding at a CAGR of 21.9% from 2018 to 2026. The key factors driving the market are the growing incidents of patients suffering from atrial fibrillation and affordable reimbursement scenario.Given the potential of the pacemaker market, the study outcome has come at the right time.Price PerformanceThe company’s shares have gained 17.3% in the past year compared with the industry’s growth of 5%. Moreover, the S&P 500 index rallied 12.9% during the same period.Zacks Rank & Other Key PicksCurrently, Medtronic carries a Zacks Rank #2 (Buy). Some other top-ranked stocks from the broader medical space are Haemonetics Corporation HAE, NuVasive, Inc NUVA and GW Pharmaceuticals plc GWPH.Haemonetics, currently sporting a Zacks Rank #1 (Strong Buy), has a projected long-term earnings growth rate at 13.5%. stocks here.NuVasive, with a Zacks Rank #2, has projected a long-term earnings growth rate of 10.9%.GW Pharmaceuticals estimates fourth-quarter earnings growth rate at 67.9%. It currently carries a Zacks Rank #2.Looking for Stocks with Skyrocketing Upside?Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.See the pot trades we're targeting>>
美敦力(Medtronic) plc MDT 公司最近公布了对 MAVEL 2的研究结果。研究结果表明, Micra 经导管起搏系统中的一套研究算法显著改善了心室间传导受损患者的同步和心脏功能,称为心房传导阻滞。该公司将于11月16日在美国心脏协会2019年美国心脏协会( AHA 科学会议)的专题科学会议上展示 MAVEL 2的结果。基于良好的结果,美美敦力(Medtronic)公司向 FDA 提交了一种新的无铅起搏器,目的是扩大显示的人群 AV 阻滞和正常窦性心律。因此,公司的目标是在研究结果良好的基础上,加强在无铅起搏器市场的立足点。 仔细看看公司的 Micra PortfolioPer , Micra TPS 是美国 FDA 批准使用的唯一无叶起搏器。与传统起搏器相比, Micra TPS 的尺寸要小得多,通过微创的方法为患者提供最先进的起搏器技术。Micra 具有创新性,因为 TPS 可以根据要求永久关闭。为什么这项研究是一个突破?根据该公司的数据,结果表明,由于升级到 Micra TPS ,心脏的心房和心室部分之间的协调将得到改善。这改善了无铅起搏器患者的外展治疗。MAVEL 2的研究评估了全世界75名患有 Micra TPS 的患者,其中40名患者有完全的心脏阻滞和正常的窦性心律,有资格纳入初步疗效分析。在达到研究的安全目标(主要终点)时没有异常的发生。最近的发展,美美敦力(Medtronic)已经见证了一系列与其心脏和血管业务相关的创新。10月,公司在日本推出了 Valiant Navion 胸腔支架移植系统,用于微创修复胸下主动脉瘤( TAA )和复杂的 B 型主动脉夹层( TBAD )。ValiantNavion 是对已经存在的 ValiantCaptivia 胸腔支架移植系统的改进。同样,在同一月,该公司推出了先进的病人程序技术的深脑刺激( DBS )治疗,使病人管理更简单和谨慎的治疗。此外,在10月,该公司还收到了 FDA 指定的完全植入式左心室辅助装置( LVAD )和 Valiant 胸腹主动脉瘤( TAAA )支架移植系统的突破装置。完全植入性 LVAD 目前处于开发阶段,拟用于晚期心力衰竭患者。瓣膜 TAAA 支架移植系统用于 TAAA 微创修复。今年9月,美美敦力(Medtronic)公司获得了美国 FDA 批准的 Evoluti PRO + TAVR 系统,这是一种创新的经导管主动脉瓣置换( TAVR )系统,该系统建立了经过验证的自我扩展,超环 Evolutit TAVR 平台。行业前景研究机构 AndMarkets 的报告显示,到2026年,全球领先心脏起搏器市场规模预计将从2017年的4710万美元增至2.698亿美元,2018年至2026年的复合年增长率为21.9%。推动这一市场的关键因素是心房颤动患者的事件日益增多,以及可负担的报销方案。考虑到起搏器市场的潜力,研究结果是在正确的时间。价格表现过去一年,该公司股价上涨了17.3%,而该行业的涨幅为5%。此外,同期标普500指数上涨12.9%。Zacks 排名和其他关键选择目前,美敦力(Medtronic)公司拥有 Zacks 排名第二(购买)。其他一些来自更广泛医疗领域的顶级股票是 Haemonitics Corporation HAE , NuVasive , Inc NUVA 和 GW Pharmaceuticals plc GWPH 。目前拥有 Zacks 排名第一( Strong Buy )的 Haemonistics 预测长期收益增长率为13.5%。这里的股票。Zacks 排名第二的 NuVasive 预测长期收益增长率为10.9%。GW Pharmaceuticals 预计第四季度收益增长率为67.9%。它目前拥有 Zacks 排名第二。在股市飙升的情况下寻找股票?Zacks 刚刚发布了一份关于合法大麻投资机会激增的特别报告。这一行业被新的全民投票和立法所忽视,预计在2021年将从原本强劲的67亿美元猛增至202亿美元。早期的投资者将会大行其道,但你必须准备好采取行动,并知道该往哪里看。请参阅我们的目标交易>>

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文